News - Dendreon

Filter

Current filters:

Dendreon

Popular Filters

Dendreon leaps as it sets out plan to launch Provenge in Europe

Dendreon leaps as it sets out plan to launch Provenge in Europe

04-03-2014

US biotech firm Dendreon says it plans to make its prostate cancer drug Provenge (autologous peripheral…

BiotechnologyDendreonEuropeMarkets & MarketingOncologyProvenge

Dendreon restructures, following poor third-quarter Provenge sales

Dendreon restructures, following poor third-quarter Provenge sales

13-11-2013

USA-based biotech firm Dendreon revealed yesterday that it is implementing a restructuring and cost reduction…

BiotechnologyDendreonFinancialOncologyProvenge

Dendreon shares surge on Provenge EU marketing approval

18-09-2013

US biotech firm Dendreon (Nasdaq: DNDN) says that the European Commission has granted marketing authorization…

DendreonEuropeOncologyPharmaceuticalProvengeRegulation

US physicians to increase use of Zytiga in chemo-naive prostate cancer patients

27-06-2012

Physicians in the USA said they would use Zytiga (abiraterone acetate), from health care giant Johnson…

DendreonJanssenJohnson & JohnsonMarkets & MarketingNorth AmericaOncologyPharmaceuticalProvengeResearchZytiga

Zytiga overtaking Provenge in MCRPC

17-01-2012

Despite no current approval of Johnson & Johnson (NYSE: JNJ) subsidiary Janssen’s Zytiga (abiraterone)…

BiotechnologyDendreonJanssenJevtanaJohnson & JohnsonMarkets & MarketingNorth AmericaOncologyPharmaceuticalProvengeSanofiZytiga

Dendreon upbeat on Provenge sales

08-01-2012

US biotech firm Dendreon (Nasdaq: DNDN) pleased investors last week when it reported that revenue of…

BiotechnologyDendreonFinancialMarkets & MarketingOncologyProvenge

Dendreon cashes in Victrelis royalty

08-12-2011

US pharma company Dendreon (Nasdaq: DNDN) says that it has agreed to sell for $125 million in cash its…

Anti-viralsBiotechnologyDendreonFinancialLicensingMerck & CoOncologyPharmaceuticalProvengeVictrelis

USA’s CMS to cover infusion costs associated with Dendreon’s Provenge

21-11-2011

Sales of Dendreon’s (Nasdaq: DNDN) new prostate cancer treatment Provenge (sipuleucel-T) have been…

BiotechnologyDendreonNorth AmericaOncologyPharmaceuticalPricingProvengeRegulation

Cancer vaccines market set to see change, will grow to over $9 billion by 2018

24-10-2011

The global cancer vaccines market in seven key markets (the USA, France, Germany, Italy, Spain, UK and…

CervarixDendreonGardasilGlaxoSmithKlineGlobalMarkets & MarketingMerck & CoOncologyPharmaceuticalProvengeVaccines

Dendreon to slash 25% of work force under restructuring plan; updates on Provenge

12-09-2011

US biotech firm Dendreon (Nasdaq: DNDN), which last month scaled back expectations for its novel prostate…

BiotechnologyDendreonFinancialGlaxoSmithKlineManagementOncologyPharmaceuticalProvenge

Volatile markets in August take a toll on US life sciences IPOs, says Burrill

04-09-2011

Market volatility in August battered life sciences companies that went public this year, wiping away…

BiotechnologyDendreonFinancialPharmaceuticalProvenge

Dendreon scales back Provenge sales forecast; 2nd-qtr 2011 net revenue climbs to $49.6 million

05-08-2011

USA-based biotech firm Dendreon (Nasdaq: DNDN) disappointed investors when, posting second-quarter 2011…

BiotechnologyDendreonFinancialOncologyPharmaceuticalProvenge

Boost for Dendreon, as CMS to cover Provenge treatment and FDA OKs production facility

04-07-2011

There was a batch of good news for Seattle, USA-based Dendreon (Nasdaq: DNDN) that support broad availability…

BiotechnologyDendreonNorth AmericaOncologyPharmaceuticalPricingProvengeRegulation

US FDA lifts clinical hold on BioSante GVAX prostate cancer vaccine

08-06-2011

BioSante Pharmaceuticals (Nasdaq: BPAX) says that the US Food and Drug Administration’s clinical…

BioSante PharmaceuticalsBiotechnologyDendreonOncologyPharmaceuticalProvengeResearch

Dendreon reduces loss in 1st-qtr 2011, with Provenge sales set to grow

04-05-2011

Seattle, USA-based biotech firm Dendreon (Nasdaq: DNDN) has reported results for the first quarter ended…

BiotechnologyDendreonFinancialProvenge

Back to top